These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10643011)

  • 1. The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders.
    Ward MS
    Pathology; 1999 Nov; 31(4):382-92. PubMed ID: 10643011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advancements of flow cytometry: new applications in hematology and oncology.
    Woo J; Baumann A; Arguello V
    Expert Rev Mol Diagn; 2014 Jan; 14(1):67-81. PubMed ID: 24308362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric immunophenotyping for hematologic neoplasms.
    Craig FE; Foon KA
    Blood; 2008 Apr; 111(8):3941-67. PubMed ID: 18198345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry in hematological disorders.
    Pati HP; Jain S
    Indian J Pediatr; 2013 Sep; 80(9):772-8. PubMed ID: 23943573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of flow cytometric immunophenotyping in malignant hematological diseases.
    Chianese R; Brando B; Gratama JW;
    J Biol Regul Homeost Agents; 2002; 16(4):259-69. PubMed ID: 12597642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Advances in diagnosis of hematological disorders.
    Choudhry VP
    Indian J Pediatr; 2013 Sep; 80(9):754-5. PubMed ID: 23943572
    [No Abstract]   [Full Text] [Related]  

  • 7. [Minimal residual disease in hematology].
    Rák K
    Orv Hetil; 2001 May; 142(21):1091-5. PubMed ID: 11449837
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
    Nosaka K; Kawaguchi T
    Nihon Rinsho; 2012 May; 70(5):835-9. PubMed ID: 22620009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry in hematological nonmalignant disorders.
    Béné MC; Le Bris Y; Robillard N; Wuillème S; Fouassier M; Eveillard M
    Int J Lab Hematol; 2016 Feb; 38(1):5-16. PubMed ID: 26542092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD43 in the malignant flow cytometry laboratory in 2020.
    Sorigue M
    Expert Rev Hematol; 2021 Jan; 14(1):123-136. PubMed ID: 33249940
    [No Abstract]   [Full Text] [Related]  

  • 11. Belgian consensus recommendations for flow cytometric immunophenotyping. The Belgian Association for Cytometry/Belgische Vereniging voor Cytometrie/Association Belge de Cytométrie.
    Van Bockstaele DR; Deneys V; Philippé J; Bernier M; Kestens L; Chatelain B; De Waele M; Demanet C
    Acta Clin Belg; 1999 Apr; 54(2):88-98. PubMed ID: 10394646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
    Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
    Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
    Flanders A; Stetler-Stevenson M; Landgren O
    Blood; 2013 Aug; 122(6):1088-9. PubMed ID: 23929839
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical uses of flow cytometry in hematological oncology].
    D'Ostilio A; Ginaldi L; Marini L; Di Gennaro A; De Martinis M; Quaglino D
    Recenti Prog Med; 1997 Apr; 88(4):157-65. PubMed ID: 9206811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
    Owen RG; Rawstron AC
    Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
    [No Abstract]   [Full Text] [Related]  

  • 16. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility.
    Dezern AE; Borowitz MJ
    Cytometry B Clin Cytom; 2018 Jan; 94(1):16-22. PubMed ID: 29236352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent publications in hematological oncology.
    Hematol Oncol; 2007 Sep; 25(3):148-55. PubMed ID: 17957827
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hematology 2010].
    Dreyling M; Subklewe M; Braess J; Spiekermann K
    Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1322-5. PubMed ID: 20556691
    [No Abstract]   [Full Text] [Related]  

  • 19. Polychromatic flow cytometry in the clinical laboratory.
    Sewell WA; Smith SA
    Pathology; 2011 Oct; 43(6):580-91. PubMed ID: 21881537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma.
    Varma S; Varma N; Reddy VV; Naseem S; Bose P; Malhotra P
    Indian J Pathol Microbiol; 2012; 55(2):206-10. PubMed ID: 22771645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.